Cardiopulmonary Bypass clinical trials at UCSF

1 research study open to eligible people

Cardiopulmonary bypass is a technique used in surgeries to temporarily take over the work of the heart and lungs. UCSF is conducting trials to evaluate the use of ravulizumab for kidney protection in patients during cardiac surgery. This research focuses on reducing surgery-related kidney complications.

Showing trials for

  • ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

    open to eligible people ages 18-90

    The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.

    San Francisco, California and other locations

Last updated: